Korean Circ J.  2025 Feb;55(2):121-131. 10.4070/kcj.2024.0154.

A Real-World, Prospective, Observational Study of Rivaroxaban on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-Valvular Atrial Fibrillation: XARENAL

• Oh IY
• Lee CH
• Choi EK
• Lim HE
• Oh YS
• Choi JI
• Ahn MS
• Kim JY
• Kim NH
• Yoon N
• Sandmann M
• Choi KJ

• KMID: 2565417
• DOI: http://doi.org/10.4070/kcj.2024.0154

Abstract

Background and Objectives
Several real-world studies have been done in patients with nonvalvular atrial fibrillation (NVAF); however, information on its safety profile in patients with renal impairment is limited. XARENAL, a real-world study, aimed to prospectively investigate the safety profile of rivaroxaban in patients with NVAF with renal impairment (creatinine clearance [CrCl], 15–49 mL/min).
Methods
XARENAL is an observational single-arm cohort study in renal impairment NVAF patients. Patients were followed up approximately every 3 months for 1 year or until 30 days following early discontinuation. The primary endpoint was major bleeding events. All adverse events, symptomatic thromboembolic events, treatment duration, and renal function change from baseline were the secondary endpoints.
Results
XARENAL included 888 patients from 29 study sites. Overall, 713 (80.3%) had moderate renal impairment (CrCl, 30–49 mL/min), and 175 (19.7%) had severe renal impairment (CrCl, 15–29 mL/min) with a mean estimated glomerular filtration rate (eGFR) of 45.2±13.0 mL/min/1.73 m 2 . The mean risk scores were 3.3±1.4 and 1.7±0.9 for CHA 2 DS 2 -VASc score and HAS-BLED score, respectively. An incidence proportion of 5.6% (6.2 events per 100 patient-years) developed major bleeding; however, fatal bleeding occurred in 0.5% (0.5 events per 100 patient-years). The mean change in the eGFR was 2.22±26.47 mL/min/1.73 m 2 per year.
Conclusions
XARENAL observed no meaningful differences in major bleeding events from other previous findings as well as renal function changes in rivaroxaban-treated NVAF patients with renal impairment, which is considered to be acceptable in clinical practice.

Keyword

Atrial fibrillation; Rivaroxaban; Renal insufficiency; Safety; Bleeding

Figure

• 

  Figure 1 Patient disposition.

• 

  Figure 2 Kaplan-Meier plot according to the occurrence of major bleeding by baseline creatinine clearance group.

Reference

1. Schnabel RB, Yin X, Gona P, et al. 50 Year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015; 386:154–162. PMID: 25960110.

2. Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc. 2015; 4:e001486. PMID: 25609415.

3. Lee SR, Choi EK. Prevalence of atrial fibrillation in Korean population. Int J Arrhythm. 2017; 18:195–204.

4. Bassand JP, Accetta G, Al Mahmeed W, et al. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: rationale for comprehensive management of atrial fibrillation. PLoS One. 2018; 13:e0191592. PMID: 29370229.

5. Wang KL, Lip GY, Lin SJ, Chiang CE. Non-vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation: meta-analysis. Stroke. 2015; 46:2555–2561. PMID: 26304863.

6. Li YG, Lee SR, Choi EK, Lip GY. Stroke prevention in atrial fibrillation: focus on Asian patients. Korean Circ J. 2018; 48:665–684. PMID: 30073805.

7. Sabir I, Khavandi K, Brownrigg J, Camm AJ. Oral anticoagulants for Asian patients with atrial fibrillation. Nat Rev Cardiol. 2014; 11:290–303. PMID: 24614113.

8. Deykin D. Warfarin therapy. 1. N Engl J Med. 1970; 283:691–694. PMID: 4916914.

9. Ten Cate H. New oral anticoagulants: discussion on monitoring and adherence should start now! Thromb J. 2013; 11:8. PMID: 23809888.

10. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133:160S–198S. PMID: 18574265.

11. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:1139–1151. PMID: 19717844.

12. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369:2093–2104. PMID: 24251359.

13. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365:981–992. PMID: 21870978.

14. Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365:883–891. PMID: 21830957.

15. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. Circulation. 2014; 130:2071–2104. PMID: 24682348.

16. Ogawa S, Aonuma K, Tse HF, et al. The APHRS’s 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation. J Arrhythm. 2013; 29:190–200.

17. Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost. 2014; 111:789–797. PMID: 24500243.

18. Bonde AN, Lip GY, Kamper AL, et al. Renal function and the risk of stroke and bleeding in patients with atrial fibrillation: an observational cohort study. Stroke. 2016; 47:2707–2713. PMID: 27758943.

19. Miyamoto K, Nakasuka K, Kusano K. Effect of renal function on anticoagulation therapy in Asian patients. Circ J. 2015; 79:2098–2099. PMID: 26329276.

20. Camm AJ, Amarenco P, Haas S, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016; 37:1145–1153. PMID: 26330425.

21. Kim YH, Shim J, Tsai CT, et al. XANAP: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia. J Arrhythm. 2018; 34:418–427. PMID: 30167013.

22. Shim J, On YK, Kwon SU, et al. A prospective, observational study of rivaroxaban for stroke prevention in atrial fibrillation: the XANAP Korea. Korean J Intern Med. 2021; 36:906–913. PMID: 32872740.

23. Liu PY, Choi EK, Kim TS, et al. XaMINA Investigators. XaMINA: a real-world, prospective, observational study of treatment-naïve patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia. Adv Ther. 2022; 39:3316–3333. PMID: 35616848.

24. Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012; 367:625–635. PMID: 22894575.

25. Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011; 32:2387–2394. PMID: 21873708.

26. van der Wall SJ, Teutsch C, Dubner SJ, et al. Anticoagulation prescription and outcomes in relation to renal function in patients with atrial fibrillation: results from GLORIA-AF. TH Open. 2021; 5:e35–e42. PMID: 33564743.

27. Chantrarat T, Hauythan S. The change of renal functions after nonvitamin K oral anticoagulants in patients with atrial fibrillation. Int J Cardiol Heart Vasc. 2021; 35:100844. PMID: 34386573.

28. National Institute for Health and Care Excellence (NICE). Chronic Kidney Disease: Assessment and Management. London: NICE;2021.

29. Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021; 23:1612–1676. PMID: 33895845.

30. Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet. 2011; 50:675–686. PMID: 21895039.